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Question: What is the independent prognostic value of tricuspid regurgitation in patients with 
heart failure? 
Findings: Using the Optum longitudinal database, a patient-level database that integrates 
multiple U.S.-based electronic health and claim records from several health care providers, we 
identified 435,679 patients with new heart failure diagnosis and both an assessment of the left 
ventricular ejection fraction and at least one year of history. Both moderate / severe prevalent 
tricuspid regurgitation (recorded prior to or within 28 days of the initial heart failure diagnosis) 
and incident tricuspid regurgitation (subsequent new cases thereafter) were associated with 
marked increases in mortality risk.   
Meaning: Tricuspid regurgitation is not an innocent bystander in patients with heart failure and 





Importance. More evidence is needed to quantify the impact of tricuspid regurgitation (TR) on 
survival in patients with heart failure (HF). 
Objective. To evaluate the independent and increment prognostic value of TR in patients with 
HF 
Design. Using the Optum database, we collected all patients diagnosed with HF between 2008 
and 2017. TR was graded as mild, moderate or severe and classified as prevalent (recorded prior 
to or within 28 days of the initial HF diagnosis) or incident (subsequent new cases of TR 
thereafter). For prevalent TR, the analysis was performed using a Cox proportional hazards 
model with adjustment for patient covariates. Incident TR was modelled as a time-updated 
covariate, as were other non-fatal events during follow-up.  
Setting. Optum ©, a de-identified electronic health records (EHR) / claims dataset that integrates 
multiple U.S.-based electronic health and claim records from several health care providers 
Participants. Patients with new HF diagnosis and both an assessment of the left ventricular 
ejection fraction (LVEF) and at least one year of history. 
Main outcome measure. All-cause Mortality 
Results. Between 2008-2017, we identified 435,679 patients with HF, at least one year of history 
and an LVEF assessment. Prevalence of mild, moderate and severe TR at baseline was 10.1%, 
5.1% and 1.4% respectively. Over a median 1.5 years follow-up, 121,273 patients (27.8%) died 
and prevalent TR was independently associated with survival. Compared to patients with no TR 
at baseline, the adjusted hazard ratios for mortality were 0.99 (95% CI 0.97-1.01), 1.17 (95% CI 
1.14-1.20) and 1.34 (95% CI 1.28-1.39) for mild, moderate and severe TR, respectively. In the 
363,270 patients free of TR at baseline, incident TR (at least mild, at least moderate, or severe) 
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developed during follow-up in 12.1%, 5.1% and 1.1% respectively. Adjusted mortality hazard 
ratios for such new cases were 1.48 (95% CI 1.44-1.52), 1.92 (95% CI 1.86-1.99) and 2.44 (95% 
CI 2.32-2.57) respectively. These findings were consistent across all patient subgroups based on 
age, gender, rhythm, associated comorbidities, prior cardiac surgery, BNP/NT-proBNP and 
LVEF.  
Conclusions. This is the first population-based evaluation of TR and patient survival in HF. 
Moderate and severe TR were associated with marked increases in mortality risk. This indicates 
that the occurrence of TR in patients with HF merits closer attention by cardiologists. 
 







Although present in over 1.6M individuals in the US, 1 tricuspid regurgitation (TR) has 
long been overlooked compared to left sided valve diseases. A recent epidemiological study 
estimated the prevalence of significant – moderate or greater - TR in the community to be as 
high as 0.55% (and up to 3% after 75 years of age), a prevalence similar to aortic valve stenosis 
(AS) or mitral valve regurgitation (MR).2, 3 TR is a heterogeneous disease usually secondary to 
other conditions (mainly left-sided disease or pulmonary hypertension) 3, 4  and it is critical to 
account for these conditions to specifically evaluate the impact of TR on survival.  
In patients with heart failure (HF), TR is highly prevalent with up to one third of patients 
having moderate or severe TR.5, 6 Despite its high prevalence, the impact of TR on survival in 
patients with HF is disputed. While several recent studies have suggested a link between the 
presence and severity of TR to worse outcomes predominantly in the context of severely reduced 
systolic function 3, 5-9, other studies have found no independent association with survival.10, 11 
Furthermore, most studies on functional TR have been modest in size, often from single tertiary 
referral centers with inherent referral bias, have focused on HF with reduced ejection fraction 
(HFrEF) and have not considered HF as a global entity (i.e. inclusive of HF with preserved EF 
(HFpEF)). These uncertainties may contribute to why TR is not included in most HF prognostic 
scoring systems such as the MAGGIC (Meta-Analysis Global Group in Chronic Heart Failure) 
score 12 and why guidelines for TR management are vague and do not involve any class I indication 
for intervention.13, 14  
Until now, evidence independently and incrementally linking TR to mortality in patients 
with HF in a large contemporary population with appropriate adjustment for associated 
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conditions has been lacking. Such evidence is essential in order to guide and enhance the 
development of new therapies and the design of appropriate clinical trials. Using the Optum 
longitudinal patient-level database, we aimed to evaluate in a large population-based study of 
patients with HF the independent and incremental impact of TR on mortality, when TR was 
diagnosed 1) prior to or at the time of the initial diagnostic of HF (prevalent TR) and 2) during 








Optum © de-identified electronic health records (EHR) / claims dataset is one of the 
largest databases in the United States, being derived from more than 85 healthcare provider 
organizations including 700 hospitals and 7,000 clinics. The database currently captures over 90 
million patients. It integrates data from EHRs and from claim records from both ambulatory and 
inpatient settings and covers diagnosis and procedure codes, laboratory results, clinical 
observations and medications. In addition, Optum Analytics uses natural language processing 
(NLP) computing technology to extract critical facts from physician notes into structured 
datasets. The NLP data provides detailed information including disease signs and symptoms (see 
supplemental materials for more information regarding NLP). Data are certified as de-identified 
by an independent statistical expert following HIPAA statistical de-identification rules and 
managed according to Optum’s customer data use agreements.  
We identified all patients in the 2008-2017 period with an ICD 9 or 10 diagnosis code of 
HF (ICD-9 428, and ICD-10 I50) and an assessment of the LV function either qualitative 
(reduced/preserved LVEF) and/or quantitative (numerical value of the LVEF) and with at least 
one year of history in the dataset prior to the initial HF episode. As ICD-9 or 10 coding do not 
provide any indication regarding TR severity, it was assessed using NLP processing of EHR 
records and semi-quantitatively graded as absent, mild, moderate or severe.   
 
Patients and disease characteristics  
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The Optum dataset contains a large number of demographic variables including age, 
gender, region, average income and race. Patients’ baseline health status and comorbidities, 
including presence and severity of valvular heart disease (TR, MR and AS) were evaluated in the 
year before the HF diagnosis using ICD 9 and 10 diagnosis codes or NLP extraction. MR and AS 
were assessed as time updated covariates to account for their impact on survival.  ICD-9/10 
procedure and Common Procedural Terminology-4 (CPT) codes were used to extract relevant 
patient procedures.  Cardiac procedures were evaluated as time updated variables to control for 
any potential impact on survival. Dialysis and PCI were assessed only during the patient’s 
baseline period. Hospitalization and medication history were ascertained by analyzing patient 
records in the 12 months prior to the initial diagnosis of HF. Other parameters extracted from 
patient records in the twelve months prior to diagnosis were body mass index, systolic and 
diastolic blood pressure, creatinine, hemoglobin, INR, BNP, NT-proBNP, albumin, ALT, AST, 
bilirubin, systolic pulmonary artery pressure (SPAP), and numerical value of LVEF. LVEF was 
considered normal above 50%, moderately reduced between 30% and 50% and severely reduced 
below 30%. Values closest to the date of the index HF diagnosis were selected. Table 1 lists all 
covariates and the completeness of the aforementioned data. 
 
Statistical analysis  
TR was analyzed according to severity (none, mild, moderate, severe) and by whether it 
was prevalent (prior or at the time of the HF diagnosis) or incident (diagnosed afterwards, during 
patient follow-up in patients free of TR at baseline). Prevalent TR was defined as TR recorded 
up to 28 days after the date of the initial HF diagnosis. We used this 28-day period to capture TR 
diagnosed using an echocardiogram that might have been performed at the time of the HF 
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diagnosis but only captured in the system within the following 4 weeks after it was performed. 
Accordingly, time at risk began 28 days after HF diagnosis in all analyses.  
Cumulative incidence of incident TR was assessed using the Kaplan Meier method. We 
assessed risk of death by TR severity using Kaplan Meier estimates and Cox proportional hazard 
models. Deaths were obtained from the Social Security Administration (SSA) Masterfile and 
censoring was based on the date of last documented encounter with the healthcare system.  
First, we compared patients according to the level of prevalent TR (at the time of the HF 
diagnosis). In a second analysis, restricted to patients free from TR at baseline, we used time-
updated categories of TR to explore the impact of incident TR on mortality. Each patient’s 
follow-up was split into time spent before and after a diagnosis of TR.15  Hazard ratios (HRs) for 
death therefore compared the hazard of death during time spent with mild, moderate or severe 
TR with the hazard during time spent without a diagnosis of TR (which also includes all patient 
time in patients who never had a diagnosis of TR throughout follow-up). At any given time, 
patients contributed time-at-risk only to the most severe category of TR for which they have 
received a diagnosis. For example, consider a patient with a diagnosis of mild TR followed by a 
diagnosis of moderate TR. From the time of diagnosis of moderate TR, the patient stopped 
contributing time to the mild TR category and began contributing time to the moderate TR 
category.  
For both prevalent and incident TR, we first fitted unadjusted Cox models for mortality. 
Next, we adjusted for covariates in the MAGGIC risk score, an established multivariate model to 
predict mortality in HF patients.12 Lastly, we adjusted for several other risk factors, including 
time-updated presence of MR and AS. We used multiple imputation with chained equations to 
impute data on missing covariates. We used 5 imputed datasets and combined estimates and 
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standard errors across datasets using Rubin’s rules.16 Sensitivity analyses used a complete case 
approach, restricting analyses to the subset of patients with complete information on all 
covariates. Multivariable Cox regression analyses were performed in the overall population and 
in pre-specified subsets based on age, gender, race, type of HF diagnosis, prior admission for HF, 
rhythm, ischemic or dilated cardiomyopathy, prior cardiac surgery, presence of permanent 
pacemaker (PPM), concomitant significant valve diseases (AS or MR), BNP/NT-proBNP, LVEF 
and SPAP. 
Continuous variables were summarized using medians with interquartile ranges, 
categorical variables as counts and percentages. Analyses were performed in Stata version 15.1, 








The initial study cohort consisted of 981,261 patients with a HF diagnosis in the period 
between 2008 and 2017, and either quantitative or qualitative information regarding LVEF. Less 
than one-year history in the dataset prior to the HF diagnosis was the main reason for exclusion 
(n=411,348; 75% of exclusions) and our final cohort consisted of 435,679 patients (see 
Supplementary Figure 1). 
The median age at baseline was 73 years (interquartile range [IQR] 63-82) and 50.8% 
were female. At baseline, 363,270 (83.4%) patients had no TR, 44,003 (10.1%) had mild TR, 
22,507 (5.1%) had moderate TR and 5899 (1.4%) had severe TR. Patients with moderate or 
severe TR were older, more frequently female, presented more frequently in AF, with associated 
MR, higher BNP/NT-proBNP and SPAP. They were also more commonly treated by diuretics 
and anticoagulant. Baseline characteristics of patients with and without TR are presented in 
Table 1. 
 
Impact of prevalent tricuspid regurgitation on outcome 
Over a median follow up of 1.5 years (IQR:0.5-3.1years), 121,273 (27.8%) patients died. 
Mortality risk was significantly associated with the severity of TR present at the time of HF  
diagnosis (Figure 1A). Unadjusted mortality rates at 2 years were 21.6% for patients free of TR, 
24.0% for mild TR, 32.7% for moderate TR and 36.9% for severe TR.  Compared to patients 
with no TR, unadjusted hazard ratios were 1.13 (95% CI, 1.11-1.15) for mild TR, 1.60 (95% CI, 
1.57 -1.64) for moderate TR, and 1.85 (95% CI, 1.78-1.93) with severe TR (Figure 2). The 
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association was less strong with progressive adjustment for potential confounders. After 
adjustment for covariates in the MAGGIC risk score, hazard ratios compared to no TR were 1.06 
(95% CI, 1.04 to 1.08) for mild TR, 1.35 (95% CI, 1.32 to 1.38) for moderate TR and 1.61 (95% 
CI, 1.54 to 1.68) for severe TR (Figure 2). Our final model also included adjustment for 
demographics, history of several comorbidities, presence of MR or AS, several biochemical 
markers, and procedures known to improve survival occurring during follow up (Figure 2). Fully 
adjusted hazard ratios compared to no TR were 0.99 (95% CI, 0.97-1.01) for mild TR, 1.17 (95% 
CI, 1.14-1.20) for moderate TR and 1.34 (95% CI, 1.28-1.39) for severe TR. Using complete 
analysis instead of multiple imputations gave very similar results.  
Figure 3A shows adjusted hazard ratios for prevalent moderate or severe TR according to 
pre-specified patient subgroups based on age, gender, race, type of HF diagnosis, prior admission 
for HF, rhythm, ischemic or dilated cardiomyopathy, prior cardiac surgery, presence of PPM, 
concomitant moderate / severe AS or MR, BNP/NT-proBNP, LVEF and SPAP.  The association 
between TR and mortality was observed in all subgroups.   
 
Impact of incident tricuspid regurgitation on outcome 
Among the 363,270 patients free from TR at baseline, within 2 years, 12.1% developed at 
least mild TR, 5.1% had at least moderate TR, and 1.1% had severe TR (Figure 4). In patients 
with HF and no TR diagnosis, the 2-year mortality risk was 20.1%. Within 2-years of an incident 
diagnosis of TR the mortality risks were 26.9% for mild TR, 39.8% for moderate TR and 51.4% 
for severe TR (Figure 1B). Compared to patients with no TR, unadjusted hazard ratios were 1.59 
(95% CI, 1.55-1.63) for mild TR, 2.64 (95% CI, 2.57-2.71) for moderate TR, and 3.61 (95% CI, 
3.46-3.77) with severe TR (Figure 2). The association remained highly significant with 
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progressive adjustment for potential confounders and even mild TR was associated with an 
increased risk of mortality. Fully adjusted hazard ratios compared with no TR were 1.48 (95% 
CI, 1.44-1.52) for mild TR, 1.92 (95% CI, 1.86-1.99) for moderate TR and 2.44 (95% CI, 2.32-
2.57) for severe TR.  As for prevalent TR, the association between incident TR and mortality 
was observed in all patient subgroups (Figure 3B). 
The increased hazard associated with an incident TR diagnosis was most marked in the 
early period after this diagnosis. Within the first month following diagnosis of severe TR, the 
adjusted hazard ratio compared with no TR was 6.10 (95% CI, 5.48-6.80) (Figure 5). The hazard 
ratio 1-3 months after diagnosis was 3.31 (95% CI, 2.94-3.72), and continued to steadily decline 
as time progressed after the diagnosis of severe TR. Beyond 2 years after diagnosis the hazard 







The results of the present study are based on a very large database coalescing electronic 
health and claim records from multiple sources and involving almost a half-million US patients 
with HF. This analysis provides unique insights into the importance of TR associated with HF. 
First, TR was commonly observed with HF, both in patients with reduced and preserved EF and 
the prevalence of TR increased with age, female gender, and with presence of concomitant AF 
and MR. Our main finding is that TR was significantly and independently associated with all-
cause mortality, with increased mortality associated with increased TR severity. Furthermore, the 
association of TR with excess mortality was consistently observed in all pre-specified subgroups 
and independent of whether LVEF was reduced or preserved. In patients free of TR at baseline, 
incident TR was associated with increased mortality after adjustment for all covariates.    
 
 The evaluation of the impact of TR on survival is challenging due to the heterogeneity of 
the disease and the frequent association with other conditions. TR is predominantly functional in 
mechanism, i.e. secondary to other conditions such as left-sided heart diseases (either 
dilated/ischemic cardiomyopathy or left-sided valvular heart disease), pulmonary hypertension or 
AF.3, 4 In a retrospective study of 5,223 patients who underwent a transthoracic echocardiogram 
at three Veterans Affairs Medical Center laboratories between 1998 and 2002, Nath et al. 
observed that mortality increased with increasing severity of TR.7 However, this study was 
performed on a selected population, predominantly men, and more severe TR was associated 
with lower LVEF, leaving the intrinsic effect of TR on survival in doubt. Following this seminal 
paper, several studies also suggested that TR was associated with worse outcomes 3, 5, 6, 8, 9, while 
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other studies did not find such association.10, 11 Recently, a meta-analysis from seventy studies 
encompassing 32,601 patients concluded to an independent association between moderate or 
severe TR and mortality 17, but could not eliminate the effect of comorbidities on mortality. In 
addition, most studies were retrospective, single center, with various referral biases, often 
initiated in the early 1990s before the full implementation of current HF treatment standards, and 
almost exclusively centered on patients with HFrEF. In the present study, in a contemporary 
setting, with a sample size 15 times larger than the meta-analysis, and with an unselected 
diagnosis of HF (HFrEF and HFpEF documented by LVEF assessment), we were able to 
demonstrate and quantify the association of increasing TR severity and mortality. The Optum 
database with more than 90 million US patients of various age, gender, race, geographic area, 
insurance type and socioeconomic status strongly suggests the generalizability of our findings. 
The excess mortality associated with TR was observed after adjustment for multiple potential 
confounders. Moderate and severe TR were associated with a 17% and 34% increased risk of 
death, respectively. Furthermore, the association between TR and mortality was consistently 
observed in all subgroups (with similar magnitude) and independent of the methods of 
adjustment (multiple imputation or complete-case analysis). The incremental relationship 
between the severity of prevalent TR and mortality was further corroborated by a similar pattern 
observed with incident TR. The higher risk of death observed with incident TR over prevalent 
TR, at each grade of TR severity, could be explained by a survival bias. The hazard ratios 
according to the time of TR diagnosis (Fig 4) would support this hypothesis.  
 Several subsets deserve specific comments. Excess mortality associated with TR was 
observed both in patients with preserved and reduced LVEF. Most of the prior studies have 
focused on patients with reduced LVEF but in the present study, approximately two thirds of 
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patients presented with preserved EF, therefore enabling to extend conclusions regarding TR and 
mortality to all patients with HF, irrespective of HFrEF or HFpEF. It has been suggested in a 
single center study of 576 patients that the impact of TR on survival decreased as EF declined.11 
Our study, taking advantage of its large size, showed that the impact of TR was highly 
significant in all LVEF subsets including those with severely reduced LVEF (below 30%). TR is 
commonly observed in patients with either primary or secondary MR. In the present study, 
increase mortality rates were observed both in patients with associated MR and in patients free of 
MR; in addition, the impact of TR on survival remained significant after adjustment for MR. AF 
is also frequently associated with TR, both as cause and consequence of the disease. The impact 
of TR on survival was observed irrespective of the presence or absence of AF in this population. 
Hence, the present study conducted in a very large cohort of patients diagnosed and treated for 
HF, shows that TR is independently linked to excess mortality in all subsets of HF. 
 
Clinical implications 
Heart failure is a major burden 18, 19 and cause of morbidity and mortality with frequent 
association of TR. Prior studies have identified risk-factors and developed HF scoring systems in 
both patients with reduced and preserved LVEF to predict survival.12, 20 However, none of those 
prognostic scoring systems have incorporated TR (presence or severity) into their modelling. TR 
has long been neglected due to lack of proven medical therapy and high mortality associated 
with surgery, reflected by the low rates of interventions performed throughout the patients’ 
lifetime.21, 22 This large cohort, extracted from a major segment of the US population (near 
population-based) clearly demonstrates that TR portends important prognostic information. 
Identification of TR either at the time or after an episode of HF, independently of any other 
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associated medical conditions and incrementally to any predictive risk score, should alert 
physicians. Those patients should be regarded as at increased risk of mortality and morbidity, 
deserve close attention and when possible, a more intensive medical management. Importantly, 
the development of TR within the following months after an index episode of HF was associated 
with an increased risk of mortality, further emphasizing the need for a rigorous follow-up of 
these patients. The impact of fast development of TR has also been suggested by others.23 
At least two studies in different settings have shown that TR per se was responsible for an 
increased risk of mortality and morbidity. Patients with tricuspid flails, a model of isolated 
severe organic TR24, and patients with isolated severe functional TR25, which accounts for 
approximately 10% of all causes of severe TR 3, 4, incurred excess mortality and morbidity risks 
including new onset of AF and congestive HF. Mirroring functional MR, determining whether 
TR is a cause or marker for the observed increased mortality risk could not be determined from 
the current results. The results of the COAPT (Cardiovascular Outcomes Assessment of the 
MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral 
Regurgitation) and MITRA-FR (Percutaneous Repair with the MitraClip Device for Severe 
Functional/Secondary Mitral Regurgitation) trials suggested that transcatheter correction, in 
selected patients with functional MR, have a positive impact on survival, HF hospitalizations and 
quality of life.26, 27 There is a need for future randomized controlled trials to evaluate the benefit 
and timing of therapeutic interventions for TR. We expect that the rapid development of 
transcatheter therapies will offer a less invasive alternative to surgery and enable the medical 
community to evaluate the impact of TR correction on clinical outcomes.28-32 Currently, TR 
correction is mainly performed at the time of concomitant mitral valve surgery and discrepancies 
between the number of patients suffering from TR and the number of tricuspid valve surgeries 
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performed in the US is consistent with the view that most TR patients are treated with 
conservative medical management.21, 22 
 
Strengths and Limitations 
Firstly, Optum is a patient-level database that integrates multiple electronic health records 
based on clinical notes without structured common echocardiographic reports, which limits the 
analysis to the data considered notable by the managing physicians. The analysis of the clinical 
notes through the NLP process greatly enhances information granularity. However, the Optum 
database remains subject to errors, omission and misreporting, but conversely reflects routine 
clinical practice. In addition, the size of the HF population examined, unique in the literature, 
may minimize the importance of such errors and reduce the variation contributed by individual 
providers and institutions. Secondly, not all variables were available for all patients. Although a 
qualitative assessment of the LVEF was available for all patients by design, a numerical value 
was missing in 12.3% and BNP and NT-proBNP values were missing in a 68.9% and 85.7% 
respectively. However, our results and interpretation were unchanged when using multiple 
imputation for missing values or a complete-case analysis. We adjusted for all available potential 
confounders but SPAP was only available in a small proportion of the population. Although we 
acknowledge this is a limitation, SPAP was available in 14,824 patients which is three times 
larger than the total available number in the entire literature.17 No information regarding right 
ventricular function was available and we were not able to account for this parameter. Thirdly, 
TR severity was graded semi-quantitatively. A quantitative assessment would have been 
desirable for TR severity 8, 9, 25 but it is not routinely performed in most institutions and an 
integrative multi-parametric approach is recommended by both the North American and 
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European Echocardiography and Cardiology Societies.33 The present evaluation thus reflects 
current real-world practice. Finally, a causal relationship between TR and mortality will only be 
fully affirmed when the treatment of TR demonstrate a survival benefit for HF patients.  
 
CONCLUSION 
In this large contemporary patient-level database of almost half-million US patients with 
a background diagnosis of HF and LVEF assessment, both prevalent and incident TR were 
independently associated with an increased risk of death that was sustained after adjustment for 
extensive potential confounders. The excess mortality was associated with increased TR severity. 
These findings indicate that TR is not an innocent bystander in patients with HF and that the 
occurrence of TR in HF patients merits closer attention by cardiologists. Future randomized 
controlled trials will evaluate the impact of TR correction on clinical outcomes and may more 
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LEGEND OF FIGURES 
Figure 1. Survival according to degree of tricuspid regurgitation (TR).  
A) TR diagnosed at baseline (prevalent TR) and B) TR diagnosed during follow-up in patients 
free of TR at baseline (incident TR) * 
*The analysis of incident TR includes only patients with no TR at baseline. For the analysis of 
incident TR, at the time of a diagnosis of TR patients are censored for the no TR category and 
begin contributing time at risk to the category of the new diagnosis (with time at risk starting 
again at time 0).    
 
Figure 2. Impact of the degree of tricuspid regurgitation (TR) on mortality risk.  
Risk is expressed as hazard ratios (95% confidence interval) relative to those with no TR.  
*Factors in MAGGIC risk score: age, sex, current smoking status, systolic blood pressure, 
diabetes, pulmonary disease, serum creatinine, beta-blocker use, ACE/ARB use. We could not 
adjust for NYHA, PASP, because of a lack of availability. 
 ** Further adjustments include adjustments for race, geographical region, type of heart failure 
(diastolic/systolic), BNP/NT-proBNP,  body mass index, heart rate, albumin, MELD-XI score, 
comorbidities, medications use at baseline, time-updated status for mitral  valve regurgitation 
and aortic stenosis, time-updated procedures (CABG,  mitral valve repair, ablation, MAZE 
procedure, pacemaker implantation) 
 
 
Figure 3. Adjusted hazard ratios of moderate and severe tricuspid regurgitation (TR) in 
selected patient subgroups relative to no TR.  
29 
 
A) prevalent TR and B) incident TR.  
*Recorded in previous year. Cardiac surgery includes coronary artery bypass graft, mitral or 
aortic valve replacement 
**Amongst the subset 14,824 patients with systolic pulmonary artery pressure measurements; 
other analyses use the full database 
 
Figure 4. Rates of incident mild, moderate and severe tricuspid regurgitation (TR) among 
the 363,270 patients free of TR at baseline. 
 
Figure 5: Adjusted hazard ratios for mortality according to the time after occurrence of 










Table 1: Baseline characteristics by presence of tricuspid regurgitation (TR) degree at baseline (prevalent tricuspid regurgitation). 








Characteristics of heart failure diagnosis     
Diagnosed with heart failure as inpatient 161214 (44.4%) 23559 (53.5%) 12444 (55.3%) 3206 (54.3%) 
Type of heart failure     
  Diastolic 217602 (59.9%) 29102 (66.1%) 14054 (62.4%) 3841 (65.1%) 
  Systolic 140992 (38.8%) 14854 (33.8%) 8422 (37.4%) 2041 (34.6%) 
  Systolic + diastolic 4676 (1.3%) 47 (0.1%) 31 (0.1%) 17 (0.3%) 
Prior (within one year) admission for heart failure  107799 (29.7%) 16855 (38.3%) 8026 (35.7%) 2087 (35.4%) 
 
Demographics 
    
Age years 73.0 (62.0 to 81.0) 75.0 (65.0 to 82.0) 80.0 (70.0 to 84.0) 80.0 (69.0 to 84.0) 
Female 
 
179877 (49.5%) 23215 (52.8%) 14095 (62.6%) 4021 (68.2%) 
Comorbidities     
Prior / current smoker 226980 (67.6%) 29120 (69.2%) 14176 (66%) 3572 (63.8%) 
Hypertension  236593 (65.1%) 29687 (67.5%) 14308 (63.6%) 3331 (56.5%) 
Hyperlipidemia  164551 (45.3%) 20818 (47.3%) 9196 (40.9%) 2005 (34.0%) 
Diabetes without complications  110885 (30.5%) 12947 (29.4%) 5161 (22.9%) 1154 (19.6%) 
Diabetes with complications  27825 (7.7%) 3232 (7.3%) 1163 (5.2%) 237 (4.0%) 
Pulmonary disease  49456 (13.6%) 6292 (14.3%) 2604 (11.6%) 544 (9.2%) 
Moderate to severe liver disease  2178 (0.6%) 362 (0.8%) 123 (0.5%) 52 (0.9%) 
Moderate to severe renal disease 70992 (19.5%) 9344 (21.2%) 4869 (21.6%) 1264 (21.4%) 
Cancer  47215 (13.0%) 6363 (14.5%) 2993 (13.3%) 655 (11.1%) 
Dilated cardiomyopathy  20329 (5.6%) 2557 (5.8%) 1164 (5.2%) 281 (4.8%) 
Coronary artery disease  121198 (33.4%) 15210 (34.6%) 6808 (30.2%) 1530 (25.9%) 
Myocardial infarction  47282 (13.0%) 6147 (14.0%) 2477 (11.0%) 467 (7.9%) 
Percutaneous coronary intervention  13905 (3.8%) 1656 (3.8%) 562 (2.5%) 71 (1.2%) 
Stroke  21037 (5.8%) 3319 (7.5%) 1575 (7.0%) 375 (6.4%) 
Cerebrovascular disease  34535 (9.5%) 5278 (12.0%) 2414 (10.7%) 524 (8.9%) 
Peripheral vascular disease  43067 (11.9%) 5893 (13.4%) 2741 (12.2%) 599 (10.2%) 
Moderate / severe mitral regurgitation 16440 (4.5%) 6403 (14.5%) 7766 (34.5%) 2506 (42.5%) 
Moderate / severe aortic stenosis 18891 (5.2%) 4973 (11.3%) 2756 (12.3%) 674 (11.4%) 
Pacemaker implantation 4073 (1.1%) 725 (1.6%) 423 (1.9%) 122 (2.1%) 
Any cardiac surgery (any procedure below) 6782 (1.9%) 1356 (3.1%) 502 (2.2%) 167(2.8%) 
Mitral valve replacement 776 (0.2%) 259 (0.6%) 178 (0.8%) 101 (1.7%) 
Aortic valve replacement 2324 (0.64%) 654 (1.49%) 233 (1.04%) 64 (1.08%) 






86708 (23.9%) 12897 (29.3%) 9670 (43.0%) 2917 (49.4%) 
Blood and echo measurements     
Creatinine, mg/dl 1.0 (0.8 to 1.4) 1.1 (0.8 to 1.4) 1.1 (0.8 to 1.5) 1.1 (0.9 to 1.5) 
NT-proBNP, pg/mL 1636 (533 to 4213) 2167 (841 to 5190) 3550 (1678 to 7207) 3815 (1945 to 7922) 
BNP, pg/mL 305 (117 to 694) 365 (154 to 766) 538 (278 to 1040) 603 (313 to 1120) 
Systolic pulmonary artery pressure, mmHg 40 (31 to 49) 40 (33 to 48) 50 (42 to 60) 55 (43 to 69) 
Left ventricular ejection fraction, % 55 (40 to 60) 55 (43 to 63) 55 (40 to 61) 55 (42 to 62) 
Albumin, g/dL 
 
3.7 (3.3 to 4.0) 3.6 (3.2 to 4.0) 3.6 (3.2 to 3.9) 3.6 (3.2 to 3.9) 
Follow-up     
Time at risk, years 1.5 (0.5 to 3.1) 1.5 (0.5 to 3.1) 1.3 (0.4 to 2.9) 1.2 (0.4 to 2.8) 
Died during follow up 96563 (26.6%) 13103 (29.8%) 8976 (39.9%) 2631 (44.6%) 
Pacemaker implantation 12460 (3.4%) 2019 (4.6%) 1291 (5.7%) 338 (5.7%) 
Any cardiac surgery (any procedure below) 14248 (3.9%) 2603 (5.9%) 1213 (5.4%) 430 (7.3%) 
Mitral valve replacement 2669 (0.7%) 601 (1.4%) 496 (2.2%) 270 (4.6%) 
Aortic valve replacement 6439 (1.8%) 1452 (3.3%) 598 (2.7%) 163 (2.8%) 
Coronary artery bypass graft 7996 (2.2%) 1180 (2.7%) 497 (2.2%) 163 (2.8%) 
Values are number of patients (percentage) or median (inter-quartiles) 
 
Missing were as follows: Prior / current smoker: 30717 (7.1%); Creatinine: 71438 (16.4%); NT-proBNP: 374782 (86.0%); BNP: 301684 (69.2%); 








Natural language processing  
We used Optum Analytics’ proprietary Natural Language Processed (NLP) data for 
determination of the concepts related to cardiac and valvular disease.  The Optum Analytics NLP 
system was developed using vocabulary from the Unified Medical Language System that 
includes multiple medical dictionaries such as the Logical Observation Identifiers Names and 
Codes (LOINC), the Systemized Nomenclature of Medicine-Clinical Terms (SNOMED-CT), 
and RxNorm, a listing of generic and branded drugs (among others). NLP Concepts are 
identified and created based on broad topics such as medications, signs, disease and symptoms, 
measurements, observations, etc. The data is harvested from the notes’ fields within the 
Electronic Health Records provided to Optum Analytics. The data used for development of each 
NLP concept is de-identified and accuracy is verified through a series of Quality Assurance steps 
prior to release for use.  Each NLP concept included in the data is associated with a unique 
subject record and a date of observation; allowing longitudinal tracking of concepts such as heart 
failure or tricuspid disease over time. Researchers using the NLP concepts can analyze and group 






Figure S1. Flow chart of the population 
  
 
981,261 patients with a diagnosis of HF 
between 2008 and 2017 
980,430 patients  
831 patients with a prior history of left 
ventricular assist device excluded 
544,751 patients without sufficient 
information on exposure or 
confounders: 
- 80,353 with no patient notes 
- 411,348 < 1 year of history in dataset 
prior to heart failure diagnosis 
- 117 missing information on age or sex 
- 9,927 patients missing date of last 
follow-up or death 
- 43,006 patients with <28 days of 
follow-up after the heart failure 
diagnosis 
435,679 patients eligible for analyses 
